Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troxatyl (troxacitabine) continuous infusion in second salvage AML
2005-001721-29Phase 2Terminated
- Sponsor
- SGX Pharmaceuticals, Inc.
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of troxerutin in acute myeloid leukemia (AML), sponsored by SGX Pharmaceuticals, Inc. Primary endpoint: Complete response rate. Started Oct 2005; status: terminated.
02
Drugs
troxerutin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-001721-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001721-29.